Literature DB >> 17916052

In silico prediction of ADMET properties: how far have we come?

John C Dearden1.   

Abstract

There have been considerable advances in the last few years in both the quantity and the quality of in silico ADMET property predictions. Most ADMET properties are now computable, and the accuracy of some of the software predictions for physicochemical properties in particular is close to that of measured data. There is, however, universal agreement that more good experimental ADMET data are needed for use in in silico model development, for models are only as good as the data on which they are based. Many data remain confidential but it is to be hoped that, with projects such as the Vitic toxicity database, being developed by Lhasa Limited, pharmaceutical companies will be prepared to release data to an 'honest broker' on a confidential basis, so that better in silico models can be developed. Incorporation of calculated ADMET properties into drug discovery and development is a multi-factorial problem and really needs a multi-factorial solution. Some progress is being made in this direction and it is hoped that within the foreseeable future software will be available for this purpose.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17916052     DOI: 10.1517/17425255.3.5.635

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  11 in total

Review 1.  Designing antimicrobial peptides: form follows function.

Authors:  Christopher D Fjell; Jan A Hiss; Robert E W Hancock; Gisbert Schneider
Journal:  Nat Rev Drug Discov       Date:  2011-12-16       Impact factor: 84.694

2.  Structure Activity Relationships (SARs) Using a Structurally Diverse Drug Database: Validating Success of Predictor Tools.

Authors:  Malcolm J D'Souza; Fumie Koyoshi; Lynn M Everett
Journal:  Pharm Rev       Date:  2009 Sep-Oct

Review 3.  Mechanisms of drug toxicity and relevance to pharmaceutical development.

Authors:  F Peter Guengerich
Journal:  Drug Metab Pharmacokinet       Date:  2010-10-22       Impact factor: 3.614

Review 4.  At the biological modeling and simulation frontier.

Authors:  C Anthony Hunt; Glen E P Ropella; Tai Ning Lam; Jonathan Tang; Sean H J Kim; Jesse A Engelberg; Shahab Sheikh-Bahaei
Journal:  Pharm Res       Date:  2009-09-09       Impact factor: 4.200

5.  ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage.

Authors:  Sichao Wang; Youyong Li; Junmei Wang; Lei Chen; Liling Zhang; Huidong Yu; Tingjun Hou
Journal:  Mol Pharm       Date:  2012-03-16       Impact factor: 4.939

6.  Extended solvent-contact model approach to blind SAMPL5 prediction challenge for the distribution coefficients of drug-like molecules.

Authors:  Kee-Choo Chung; Hwangseo Park
Journal:  J Comput Aided Mol Des       Date:  2016-07-23       Impact factor: 3.686

7.  In Silico Augmentation of the Drug Development Pipeline: Examples from the study of Acute Inflammation.

Authors:  Gary An; John Bartels; Yoram Vodovotz
Journal:  Drug Dev Res       Date:  2011-03-01       Impact factor: 4.360

8.  Extracting Relevant Information from FDA Drug Files to Create a Structurally Diverse Drug Database Using KnowItAll®

Authors:  Malcolm J D'Souza; Fumie Koyoshi
Journal:  Pharm Rev       Date:  2009-05-08

9.  Reactivity measurement in estimation of benzoquinone and benzoquinone derivatives' allergenicity.

Authors:  Wilbes Mbiya; Itai Chipinda; Reuben H Simoyi; Paul D Siegel
Journal:  Toxicology       Date:  2015-12-02       Impact factor: 4.221

Review 10.  Structure-based ligand design and the promise held for antiprotozoan drug discovery.

Authors:  William N Hunter
Journal:  J Biol Chem       Date:  2008-12-22       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.